Eledon Pharmaceuticals, Inc.
ELDN Healthcare Biotechnology
In the quarter to June 2026, EPS fell 107.7% and free cash flow fell 28.0%, each against the same quarter a year earlier.
Follow ELDN
Eledon Pharmaceuticals, Inc. (ELDN) Altman Z-score
Altman Z-score, annual
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|
How the score is made up
There are no annual figures to work it out from.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| UPB Upstream Bio, Inc. compare | 61.0× |
| IVVD Invivyd, Inc. compare | 2.9× |
| ACOG Alpha Cognition Inc. compare | 2.5× |
| CGEN Compugen Ltd. compare | −0.4× |
| PRQR ProQR Therapeutics N.V. compare | −4.4× |
| RNAC Cartesian Therapeutics, Inc. compare | −4.7× |
| LYEL Lyell Immunopharma, Inc. compare | −5.1× |
| ELDN Eledon Pharmaceuticals, Inc. | — |
| SION Sionna Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets